BioWorld

June 23, 2010

Regulus Inks $750M Pre-Target miRNA Deal with Sanofi-Aventis

Regulus Therapeutics Inc. landed its biggest partnership to date: a $750 million deal with Sanofi-Aventis Group SA aimed at discovering microRNA-based drugs against four fibrosis targets. (BioWorld Today) Read More

Diamyd Climbs on $625M Type I Diabetes Deal with Ortho-McNeil

Metabolex, J&J Unit Sign $330M Deal for Type II Diabetes Drugs

Cadence 'Incline'd Toward Pain Market in Late-Stage Option Deal

Corrections & Clarifications

Other News To Note

Stock Movers

Clinic Roundup

Financings Roundup

Today's news in brief

BioWorld

BioWorld briefs for April 2, 2026.

With improved technologies, biomarkers, failed drugs may come into their own

BioWorld

At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...

Comparison of neurons in a healthy brain and nerve cells in neurodegenerative disease with amyloid plaques

Small-molecule TREM2 agonist advances to treat Alzheimer’s

BioWorld Science

Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...

Amlogenyx’s AM-805 reduces amyloid plaques in AD

BioWorld Science

The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 31, 2026